Maintain TMO at $599.69; add on pullback to $575-580 or breakout above $608.52
Maintain current TMO exposure at $599.69 without adding. The $575-580 add-zone and $566 stop are preserved from prior analysis but are not the sole re-engagement path—the $608.52 breakout confirmation is an equally valid entry trigger. No adds before the structural setup resolves either via confirmation (close above $608.52 on volume) or correction (pullback to the 10 EMA zone at $575-580). Position sizing remains at current exposure.
| Position | Action |
|---|---|
| Confirmed close above $608.52 on volume | Trim 10-15% of position |
| Price at $575-580 (10 EMA / breakout zone) | Add to position with hard stop at $566 |
| Price at $583 | Trail stops (1× ATR) |
| Golden cross confirmed and Q3 print in late October | Reassess position |
TMO is a structural compounder accelerating out of a post-COVID trough, not a stretched name begging for a pullback — the bear thesis conflates investment-mode cash flow with operational decay, misreads overbought technicals as exhaustion signals, and applies a trailing P/E lens to a company with 48% embedded EPS growth.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | $578.31 | bullish |
| close_50_sma | $519.69 | bullish |
| close_200_sma | $531.24 | bullish |
| macd | 20.58 | bullish |
| rsi | 73.20 | bearish |
| boll_ub | $608.52 | neutral |
| boll_lb | $513.04 | neutral |
| atr | $16.35 | neutral |
Support: 580 · 578.31 · 560.78 · 531.24 · 519.69 · 513.04 | Resistance: 600 · 608.52
TMO is in a structurally strong uptrend with price at $599.69, up +37.0% from the May 15 swing low of $437.90. All three moving averages confirm bullish alignment (10 EMA $578.31, 50 SMA $519.69, 200 SMA $531.24), with a golden cross likely within 1-3 weeks as the 50 SMA closes on the 200 SMA (spread of only $11.55). MACD at +20.58 with expanding histogram confirms strengthening momentum, but RSI at 73.20 signals overbought conditions with elevated short-term pullback risk. ATR of $16.35 suggests trailing stops near $583 (1× ATR) or $575 (below 10 EMA). Support stacks at $580 (breakout zone), $578.31 (10 EMA), and $560.78 (20 SMA middle band), while resistance sits at $600 (psychological) and $608.52 (upper Bollinger Band). Overall recommendation is HOLD for existing positions with Buy-on-pullback to $578-$580 zone for new entries targeting $608-$620.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed close above $608.52 on volume
Then: Trim 10-15%
EV: +$620+ (upper Bollinger Band $608 → $620+ on continuation) · concedes: Goodwill at 45% of assets and D/E at 73.7% are real risks — but typical for healthcare tools and manageable with $9.85B cash and $6.3B FCF; The 4-year OCF decline is a legitimate data point — but reflects investment mode and working capital build, not terminal decline; RSI at 73.20 is elevated — but no divergence exists and stock rallied to fresh highs after touching that level
TMO is a late-stage momentum entry at $599.69 with overbought technicals (RSI 73.2, upper Bollinger Band), fragile "inflection" narrative dependent on M&A-driven revenue, 4 consecutive years of declining cash flow, a balance sheet impaired by 45% goodwill with negative tangible book value, and macro headwinds (86% probability of zero Fed cuts in 2026) that make a premium 21.8x forward P/E unjustifiable for a company with essentially flat revenue growth.
EV: -$25 to -$30 (pullback to $570-575 zone) or flush to $531 (200 SMA)
→ vs conservative: Waiting for a pullback to 575-580 is opportunity cost disguised as prudence; TMO at 599.69 with imminent golden cross, fresh FDA catalysts, raised guidance, and DHR underperformance as relative tailwind is not a setup that rewards patience
→ vs conservative: RSI overbought framing is anchoring to mean-reversion heuristics that don't apply when the underlying catalyst is fresh and structural
→ vs neutral: Framing bull and bear cases as 'genuetically balanced' is intellectually lazy; backward-looking data points (-9.8% OCF decline, -0.2% CAGR) do not negate the structural inflection now underway
→ vs neutral: The neutral analyst completely underweights the competitive read: TMO raised guidance while DHR did not, driving institutional flows into the life-sciences duopoly leader
Market Cap
$221.73B
Share Price
~$517
52-Week Range
$435.27 – $643.99
Beta
0.85
Dividend Yield
0.32%
Trailing P/E
32.26
Forward P/E
21.80
PEG Ratio
1.94
P/B Ratio
4.21
Revenue 2022
$44,915M
Revenue 2023
$42,857M
Revenue 2024
$42,879M
Revenue 2025
$44,557M
Net Income 2025
$6,704M
Diluted EPS 2025
$17.74
Forward EPS Consensus
$27.51
Gross Margin TTM
41.0%
Operating Margin TTM
18.8%
Net Margin TTM
15.0%
ROE
13.5%
ROA
5.1%
R&D Spend 2025
$1.40B
SG&A 2025
$8.73B
Interest Expense 2025
$1.42B
Restructuring/M&A Costs 2025
$362M
Total Assets
$110.34B
Total Debt
$39.39B
Long-term Debt
$35.85B
Net Debt
$29.53B
Stockholders' Equity
$53.41B
Debt/Equity
73.7%
Current Ratio
1.55
Goodwill
$49.36B
Other Intangibles
$15.84B
Tangible Book Value
-$11.79B
Treasury Stock
$22.31B
Diluted Shares Outstanding
378M
Operating Cash Flow 2022
$9,154M
Operating Cash Flow 2023
$8,406M
Operating Cash Flow 2024
$8,667M
Operating Cash Flow 2025
$7,818M
Free Cash Flow 2022
$6,911M
Free Cash Flow 2023
$6,927M
Free Cash Flow 2024
$7,267M
Free Cash Flow 2025
$6,293M
CapEx 2025
$1,525M
M&A Spend 2025
$4,037M
Dividends 2025
$636M
Share Buybacks 2025
$3,000M
Cash Position
$9.85B
FCF Yield
~2.8%
Strengths
Concerns
Thermo Fisher Scientific is a high-quality mega-cap healthcare compounders in transition, having recovered from post-COVID headwinds with 2025 revenue of $44.56B (+3.9%) and EPS returning to peak levels ($17.74). The stock trades at a premium (32.3x trailing P/E, 4.2x P/B) pricing in ambitious forward EPS growth of 48%, while facing headwinds from four consecutive years of declining operating cash flow, $49.36B in goodwill (45% of assets), and negative tangible book value. The aggressive M&A strategy ($4B+ annual deals) and $3B annual buyback program support the equity story but require flawless execution to justify the valuation, leaving limited margin of safety.
Macro: Oil surging on fading Strait of Hormuz reopening hopes; Treasury yields rising on inflation-fear spillover. Fed-cut odds firmly pricing restrictive stance (86% probability of zero cuts in 2026). Soft-landing consensus intact (US recession 8%). Inflation expectations moderating despite oil spike.